SCHEMBL14339042

SCHEMBL14339042

CC(C(=O)NCCCCCCc1ccc(Cl)cc1)N1C(=O)CC1SCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.46
MEN1 O00255 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 2/20 0.46
PLAAT3 P53816 1/20 0.45
PLAAT5 Q96KN8 1/20 0.45
PLAAT2 Q9NWW9 1/20 0.45
PLAAT4 Q9UL19 1/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HPGD P15428 1/20 0.41
ASAH1 Q13510 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14514859 0.91 KMT2A (0.43) MAPTKMT2AALDH1A1CYP2D6CYP2C9
SCHEMBL8439155 0.81 PLAAT3 (0.47) KMT2ALMNAL3MBTL1ALDH1A1PLAAT3
SCHEMBL8438577 0.81 PLAAT3 (0.47) KMT2ALMNAL3MBTL1ALDH1A1PLAAT3
SCHEMBL8440368 0.81 PLAAT3 (0.47) KMT2ALMNAL3MBTL1ALDH1A1PLAAT3
SCHEMBL8438842 0.81 PLAAT3 (0.47) KMT2ALMNAL3MBTL1ALDH1A1PLAAT3
SCHEMBL8552407 0.80 SLC1A2 (0.58) KMT2ALMNAMEN1ALDH1A1
SCHEMBL8438510 0.80 LMNA (0.42) LMNAL3MBTL1ALDH1A1PLAAT3PLAAT5
SCHEMBL8594066 0.79 HDAC3 (0.45) KMT2AMEN1ASAH1
SCHEMBL8595742 0.76 KMT2A (0.40) KMT2AMEN1ASAH1
SCHEMBL8440266 0.75 ACE (0.46) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070292385-A1 Phospholipase Inhibitors Localized in the Gastrointestinal Lumen ILYPSA, INC. 2007-12-20 US disclosed
US-20070292385-A1 Phospholipase Inhibitors Localized in the Gastrointestinal Lumen ILYPSA, INC. 2007-12-20 US disclosed
US-20070135383-A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors ILYPSA, INC. 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135383-A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors PNLIP, PLA2G2E, PLA2G3 MAPT 4260/4885KMT2A 2990/4885LMNA 1895/4885
US-20070292385-A1 Phospholipase Inhibitors Localized in the Gastrointestinal Lumen PNLIP, PLA2G2E, PLA2G4B MAPT 4733/4885KMT2A 3141/4885LMNA 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.